[Market Feature] Pharos iBio Surges 9% on Expectations for Accelerated Technology Transfer Talks at 'Bio-Europe'

Pharos iBio is showing strong performance in early trading.

As of 9:35 a.m. on October 28, Pharos iBio was trading at 5,350 won, up 9.52% (465 won) from the previous day.

Investor sentiment appears to have been boosted by news that the company will participate in 'Bio-Europe 2025,' the largest pharmaceutical and biotech event in Europe, which will be held in Vienna, Austria, from November 3 to 5 (local time).

At this event, Pharos iBio plans to explore various business opportunities, including deepening discussions on technology transfer for its next-generation acute myeloid leukemia (AML) treatment, 'PHI-101,' which has successfully completed global Phase 1 clinical trials, as well as 'PHI-501,' a treatment for refractory solid tumors that is about to enter Phase 1 clinical trials, in meetings with global pharmaceutical and biotech companies.